Full-Time
Medicare Advantage plans with on-demand care
$113.3k - $170k/yr
Remote in USA
Remote
Bachelor's, Master's
See people who can refer or advise you
Alignment Health delivers Medicare Advantage plans for seniors, offering 24/7 access to healthcare through in-person, in-home, or telehealth options. Plans are funded by premiums paid by Medicare beneficiaries and federal reimbursements, with a focus on coordinated care supported by provider-facing technology to improve delivery and efficiency. Differentiation comes from pairing high-touch, VIP-level service with affordable pricing and technology-driven care coordination. The overarching goal is to simplify and enhance the healthcare experience for seniors by providing accessible, high-quality care without excessive costs.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Orange, California
Founded
2013
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Alignment Health, a Medicare Advantage insurer, has secured a $200 million credit line from Citibank to fund potential acquisitions and market expansion. The three-year credit facility, established on 26 February, will support purchases of healthcare delivery groups, standalone and provider-sponsored MA plans, and other risk-bearing assets in targeted geographies. As of 30 June, the company had not drawn on the credit line. Alignment currently operates in 45 markets with 294,100 health plan members. The insurer previously outlined a similar acquisition strategy in its 2021 initial public offering filing. Its last acquisition was California's Citizens Choice Health Plan in 2014, which rebranded as Alignment Health Plan the following year.
Alignment Healthcare (NASDAQ:ALHC) posts earnings results, beats estimates by $0.04 EPS. July 30, 2026 Key points. * Alignment Healthcare exceeded second-quarter expectations, reporting $0.17 in EPS versus the $0.13 consensus and $1.34 billion in revenue versus $1.31 billion expected. * Membership grew 31% year over year to 294,100, while adjusted EBITDA rose 48% to $68 million. Management raised its 2026 membership and guidance outlook and sees approximately $880 million in embedded adjusted gross profit potential. * Near-term risks include seasonally weaker third-quarter profitability, higher-acuity members and increased investments. Separate law-firm investigations into potential securities-law violations add legal and investor uncertainty, though they do not establish wrongdoing. * Five stocks we like better than Alignment Healthcare. Alignment Healthcare (NASDAQ:ALHC - Get Free Report) issued its earnings results on Thursday. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of $0.13 by $0.04, FiscalAI reports. Alignment Healthcare had a net margin of 0.47% and a return on equity of 11.50%. The firm had revenue of $1.34 billion during the quarter, compared to analyst estimates of $1.31 billion. Here are the key takeaways from Alignment Healthcare's conference call: * Strong second-quarter results: Membership rose 31% year over year to 294,100, revenue increased 32% to $1.3 billion, and adjusted EBITDA grew 48% to $68 million, with a 60-basis-point margin expansion. * Alignment raised its 2026 membership and revenue outlook, increased the low end of its adjusted gross profit guidance by $10 million and adjusted EBITDA guidance by $7 million, and remains on track for its full-year targets. * Management estimates approximately $880 million of embedded adjusted gross profit potential in its current membership base, as roughly half of members remain in their first or second year and are expected to become more profitable as clinical programs mature. * The latest AVA AI stratification model can identify the 10% of members expected to account for nearly 70% of hospital admissions over the following 30 days, supporting more targeted intervention by Care Anywhere teams. * Third-quarter profitability is expected to be seasonally weaker, with only about 30% of full-year adjusted EBITDA projected in the second half; higher-acuity new members, Part D trends, and additional clinical, AI, automation, hiring, and market-preparation investments are expected to pressure MBR and SG&A. Alignment Healthcare price performance. Shares of Alignment Healthcare stock traded up $0.32 during trading on Thursday, hitting $18.61. The stock had a trading volume of 4,016,545 shares, compared to its average volume of 4,371,387. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 1.56. Alignment Healthcare has a 12 month low of $12.91 and a 12 month high of $25.12. The firm has a market cap of $3.85 billion, a price-to-earnings ratio of 206.78, a P/E/G ratio of 2.49 and a beta of 1.05. The business's 50-day moving average is $19.69 and its 200 day moving average is $19.81. Key headlines impacting Alignment Healthcare. Here are the key news stories impacting Alignment Healthcare this week: * Positive Sentiment: Alignment Healthcare reported second-quarter EPS of $0.17, exceeding the $0.13 analyst consensus, while revenue of $1.34 billion surpassed expectations of $1.31 billion. Management said results exceeded the high end of guidance across key metrics. Alignment Healthcare Reports Second Quarter 2026 Results * Positive Sentiment: The earnings beat provides a favorable near-term catalyst, supported by a reported 11.50% return on equity and a 0.47% net margin, although profitability remains modest. * Neutral Sentiment: Alignment Healthcare maintained third-quarter revenue guidance of approximately $1.3 billion, in line with consensus estimates. Full-year 2026 revenue guidance of approximately $5.2 billion also matched expectations. No EPS figures were provided in the supplied guidance updates. * Neutral Sentiment: A Zacks comparison characterized ALHC as a potential value-stock candidate relative to PACS Group, but this represents an investment-screening view rather than a change in company fundamentals. PACS or ALHC: Which Is the Better Value Stock Right Now? * Negative Sentiment: Kaplan Fox, Lowey Dannenberg and Pomerantz announced investigations into potential federal securities-law violations. These announcements appear related to allegations concerning Alignment Healthcare and may increase legal, reputational and investor uncertainty; the investigations do not establish wrongdoing. Lowey Dannenberg Investigation Analysts set new price targets. Several equities research analysts have issued reports on ALHC shares. UBS Group restated a "neutral" rating on shares of Alignment Healthcare in a research report on Wednesday, July 8th. Weiss Ratings upgraded Alignment Healthcare from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Thursday, May 7th. Wall Street Zen raised Alignment Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, May 9th. Barclays cut their target price on Alignment Healthcare from $19.00 to $16.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 26th. Finally, Wolfe Research began coverage on Alignment Healthcare in a research report on Friday, April 17th. They set an "outperform" rating and a $24.00 price target on the stock. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Alignment Healthcare has a consensus rating of "Moderate Buy" and a consensus target price of $24.30. Insider activity at Alignment Healthcare. In related news, insider Hyong Kim sold 35,951 shares of the business's stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $19.86, for a total transaction of $713,986.86. Following the completion of the transaction, the insider directly owned 331,750 shares in the company, valued at $6,588,555. The trade was a 9.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John E. Kao sold 298,000 shares of the company's stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $19.86, for a total value of $5,918,280.00. Following the completion of the transaction, the chief executive officer owned 1,088,766 shares in the company, valued at $21,622,892.76. This represents a 21.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,039,951 shares of company stock valued at $19,976,967 in the last ninety days. 5.20% of the stock is currently owned by corporate insiders. Institutional trading of Alignment Healthcare. A number of hedge funds have recently made changes to their positions in the stock. Summit Securities Group LLC bought a new stake in Alignment Healthcare in the 4th quarter worth approximately $26,000. Larson Financial Group LLC purchased a new stake in shares of Alignment Healthcare in the 3rd quarter valued at $33,000. Parallel Advisors LLC grew its holdings in shares of Alignment Healthcare by 87.7% during the 4th quarter. Parallel Advisors LLC now owns 1,654 shares of the company's stock valued at $33,000 after purchasing an additional 773 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Alignment Healthcare during the 3rd quarter valued at $53,000. Finally, Wexford Capital LP purchased a new position in Alignment Healthcare in the 3rd quarter worth $164,000. 86.19% of the stock is owned by institutional investors. About Alignment Healthcare. Alignment Healthcare, Inc NASDAQ: ALHC is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience. At the core of Alignment Healthcare's approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Alignment Healthcare, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alignment Healthcare wasn't on the list. While Alignment Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Securities fraud investigation into Alignment Healthcare, Inc. (NASDAQ: ALHC) following whistleblower lawsuit of Financial manipulation. LOS ANGELES-(BUSINESS WIRE)-Glancy Prongay Wolke & Rotter LLP today continues its investigation on behalf of Alignment Healthcare, Inc. ("Alignment" or the "Company") (NASDAQ: ALHC) investors concerning the Company's possible violations of the federal securities laws after the stock price fell 16% on July 8, 2026. What Happened? On July 8, 2026, reports emerged that a former Alignment executive had filed a whistleblower lawsuit alleging that the Company manipulated its finances to boost its stock price and executive compensation. The lawsuit, filed by the former chief transformation officer, alleges that Alignment deliberately misclassified $8 million to $10 million in routine operating expenses (such as routine software maintenance and production support) as capital expenditures within its technology sector, thereby artificially inflating the Company's adjusted EBITDA and enabling the Company to report its "first full year of positive adjusted EBITDA as a public company". On this news, Alignment's stock price fell $4.02, or 16.7%, to close at $20.03 per share on July 8, 2026, thereby injuring investors. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ALIGNMENT HEALTHCARE, INC. (ALHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. About Glancy Prongay Wolke & Rotter LLP GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm's recent successes, GPWR was named one of Law360's Securities Groups of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome. Contacts. Glancy Prongay Wolke & Rotter LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 Charles Linehan Email: [email protected] Telephone: 310-201-9150 Toll-Free: 888-773-9224 Visit its website at: www.glancylaw.com. More News From Glancy Prongay Wolke & Rotter LLP LOS ANGELES-( BUSINESS WIRE )-Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Microvast Holdings, Inc. ("Microvast" or the "Company") (NASDAQ: MVST) common stock between April 1, 2025 and March 16, 2026, inclusive (the "Class Period"). Microvast investors have until September 21, 2026 to file a lead plaintiff motion. IF YOU SUFFE... LOS ANGELES-( BUSINESS WIRE )-Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON CAPRICOR THERAPEUTICS, INC. (CAPR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Wh... LOS ANGELES-( BUSINESS WIRE )-Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired PROCEPT BioRobotics Corporation ("PROCEPT" or the "Company") (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"). PROCEPT investors have until September 22, 2026 to file a lead plaintiff motion.IF Y... Glancy Prongay Wolke & Rotter LLP. NASDAQ:ALHC Release Summary Whistleblower suit alleges Alignment misclassified $8-10M as capex to inflate EBITDA. Stock fell 16.7% to $20.03 on 7/8/26 news. Release Versions Glancy Prongay Wolke & Rotter LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 Charles Linehan Email: [email protected] Telephone: 310-201-9150 Toll-Free: 888-773-9224 Visit its website at: www.glancylaw.com.
Whistleblower lawsuit accuses Alignment of accounting fraud. A former executive is claiming that the MA insurer recorded millions of dollars as capital expenditures that should have been operating expenses, inflating its value. Alignment strongly denied the allegations.
Alignment Health Plan recognized as one of four Medicare Advantage prescription drug plans in the U.S. for 2026 Excellence in Quality. GlobeNewswire | Alignment Healthcare USA, LLC Yesterday at 1:01pm PDT ORANGE, Calif., May 14, 2026 (GLOBE NEWSWIRE) - Alignment Healthcare, Inc. (NASDAQ: ALHC) has been recognized for excellence in quality for its Medicare Advantage prescription drug (MAPD) plan by the Pharmacy Quality Alliance (PQA). Out of 613 eligible contracts, only 1.6% achieved recognition, highlighting the significance of this award. The recognition marks the seventh time Alignment has received this award, reinforcing its dedication to providing the best care for seniors. The PQA has measured medication safety for the Centers for Medicare and Medicaid Services (CMS) since 2006, ensuring medication safety, adherence and appropriate use. "We are incredibly honored that Alignment Health Plan has once again been recognized by PQA as a national leader in medication safety and adherence," said Dawn Maroney, CEO, Alignment Health Plan. "Being one of only four MAPD plans to earn the 2026 Excellence in Quality Award reinforces our mission to put seniors first. By combining sophisticated data analytics with personalized care, we continue to bridge care gaps and empower our members to live their healthiest, most vibrant lives." The 2026 PQA Laura Cranston Excellence in Quality Award goes to MAPDs with at least a 4.5-star Part D summary rating and a perfect 5-star rating on all five PQA medication measures used in CMS's star ratings program. Alignment Health was one of four MAPDs that earned the perfect rating on the following five PQA measures: medication adherence for diabetes medications; medication adherence for hypertension (RAS antagonists); medication adherence for cholesterol (statins); medication therapy management program completion rate for comprehensive medication reviews; and statin use in persons with diabetes. CMS evaluates Medicare plan quality every year based on a 5-star rating system. Alignment's MAPD plans provide prescription drug coverage with personalized support to help members - particularly those managing multiple chronic conditions - access the medicine they need to stay healthy. The company continues to differentiate itself through its comprehensive, data-driven pharmacy initiatives designed to reduce medication-related risks and improve adherence. These efforts are supported by close collaboration with providers and pharmacies to deliver coordinated, patient-centered care, promoting the safe and timely use of appropriate medications. "This recognition reflects our unwavering focus on quality and our commitment to delivering safe, effective, and high-quality pharmacy care for the seniors who place their trust in us," said Ruby Liu, senior vice president of pharmacy, Alignment Health. "While we are proud to receive this honor, we are even more proud of the meaningful impact our pharmacy programs have on our members' daily lives. Our team remains firmly committed to continuous improvement as expectations for pharmacy quality continue to rise." Alignment Health Plan received the PQA Excellence in Quality Award in 2025, from 2018 to 2022 and the PQA Quality Improvement Award in 2018, becoming the first health plan to receive both PQA awards in the same year. The PQA has recognized Medicare prescription drug plans for their achievements in medication safety since 2011. About Alignment Health Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health's mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA(R). As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com. This is a paid placement. For further inquiries, please contact GlobeNewswire directly.